Final answer:
When starting a patient on an ACE-I or ARB, the dose may be titrated based on serum potassium levels to prevent hyperkalemia.
Step-by-step explanation:
When starting a patient on an ACE-I (Angiotensin-Converting Enzyme Inhibitor) or ARB (Angiotensin Receptor Blocker), the dose may be titrated based on serum potassium levels.
Both ACE-Is and ARBs can cause an increase in serum potassium levels. This is because they work by blocking the renin-angiotensin-aldosterone system, which normally promotes the excretion of potassium by the kidneys. By blocking this system, the medications can decrease the excretion of potassium, leading to an increase in serum levels.
Monitoring potassium levels is important to prevent hyperkalemia, which is a potentially serious condition characterized by high levels of potassium in the blood.